Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Aura Biosciences brings in $8mm through Series C round

Executive Summary

Aura Biosciences Inc. (cancer therapies) raised $8mm through what appears to be its Series C round from existing investors Henri Termeer (former Genzyme CEO; also joins Aura's board), Advent Partners, Chiesi Ventures, Ysios Capital, Alexandria Venture Investments, and other individual backers. Funds will help advance AU011, the company's lead project for ocular melanoma, into clinical trials.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies